

## Kidney Suite Post-Consultation meeting minutes

### Kidney Suite Guideline Update – Post-Consultation Committee Meeting – day 2

**Date:** 14/05/2021

**Location:** Virtual

**Minutes:** Draft

<b>Committee members present:</b>	
Tony Wierzbicki (Chair) (AW)	Present for notes 1 – 6
Andrew Lewington (Vice Chair) (AL)	Present for notes 1 – 6
Clare Allinson (CA)	Present for notes 1 – 6
Virginia Aylett (VA)	Present for notes 1 – 6
Tara Bashford (TB)	Present for notes 1 – 6
Neel Basudev (NB)	Present for notes 1 – 6
Ivan Bennett (IB)	Present for notes 1 – 6
Grainne Connolly (GC)	Present for notes 1 – 6
Jan Dudley (JD)	Present for notes 1 – 6
Hugh Gallagher (HG)	Present for notes 1 – 6
Deepa Kariyawasam (DK)	Present for notes 1 – 6
Arif Khwaja (AK)	Present for notes 1 – 4
Fiona Loud (FL)	Present for notes 1 – 6
Catherine Pogson (CP)	Present for notes 1 – 6

<b>In attendance:</b>		
Steph Armstrong (SA)	Technical Analyst	Present for notes 1 – 6
Victoria Axe (VX)	Guideline Commissioning Manager	Present for notes 1 – 6
Lucy Beggs (LB)	Health Economic Adviser	Present for notes 1 – 6
Chris Carmona (CC)	Senior Technical Adviser	Present for notes 1 – 6
Jackie Durkin (JDK)	Administrator	Present for notes 1
James Hall (JH)	Editor	Present for notes 1 – 6
Kathryn Hopkins (KH)	Technical Adviser	Present for notes 1 – 6

## Kidney Suite Post-Consultation meeting minutes

Jon Littler (JL)	Project Manager	Present for notes 1 – 6
Anne-Louise Clayton (ALC)	Editor	Present for notes 1 – 6
Kusal Lokuge (KL)	Health Economic Analyst	Present for notes 1 – 6
Yolanda Martinez (YM)	Technical Analyst	Present for notes 1 – 6
Joshua Pink (JP)	Health Economic Adviser	Present for notes 1 – 6
Susan Spiers (SS)	Associate Director	Present for notes 1 – 6

### Apologies:

Sarah Ali	Committee member
Roy Connell	Committee member
Linda Grainger	NICE - Editor
Rajib Pal	Committee member
Nicola Thomas	Committee member

### 1. Welcome and objectives for the meeting

The Chair welcomed the committee members and NICE attendees to day 2 of the post-consultation committee meeting on Kidney Injury & Disease.

The Chair informed the committee that apologies had been received which are noted above.

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair reminded FL that she would not be able to contribute to the discussion in section 3 due to declared conflicts with Astra Zeneca. No further interests were declared.

The Chair reviewed the minutes from GComm14 and GComm15. He asked the Committee that if they wanted any changes to the minutes, they could forward comments to JL.

### 2. Measuring kidney function:

- **Recommendation 1.1.3**

The Chair introduced Yolanda Martinez (YM), Technical Analyst, who presented consultation comments to the committee around recommendation 1.1.3.

The committee provided their feedback on how to respond to stakeholder comments

## Kidney Suite Post-Consultation meeting minutes

and the Chair thanked YM for her presentation.

### 3. Discussion of SGLT2 inhibitors

- **Health economics – new study on canagliflozin.**
- **Health economics model from the type 2 diabetes update.**
- **Changes to recommendation 1.6.6.**
- **Comments on eGFR decline and monitoring.**
- **Other comments on SGLT2 inhibitors.**
- **Research recommendation: managing proteinuria.**

The Chair introduced KH (Technical Lead) and JP (Health Economic Adviser) who opened the committee discussion on SGLT2 inhibitors and presented the research recommendations on managing proteinuria.

The committee provided feedback and the Chair thanked KH and JP for their presentation.

The Chair introduced LB (Health Economic Adviser) and KL (Health Economic Analyst) who presented the economic models for canagliflozin and for type 2 diabetes and asked the committee for their feedback.

The Chair thanked LB and KL for their presentations.

The Chair introduced YM (Technical Analyst) who presented consultation comments to the committee on the changes to recommendation 1.6.6, eGFR decline and monitoring, and other comments on SGLT2 inhibitors.

The committee provided their feedback on how to respond to stakeholder comments and the Chair thanked LB, KL, JP and KH for her presentations.

### 4. Investigations for proteinuria

- **Recommendation 1.1.11**
- **Recommendation 1.1.12**
- **Recommendation 1.1.13**

The Chair introduced YM (Technical Analyst) who presented consultation comments to the committee around proteinuria.

The committee provided their feedback on how to respond to stakeholder comments and the Chair thanked YM for her presentation.

### 5. Who should be tested for CKD?

- **Recommendation 1.1.21**
- Algorithm: identifying CKD in adults**
- **Recommendation 1.1.25**
- Recommendations for research**
- **Uric acid lowering agents**

The Chair introduced YM (Technical Analyst) who presented consultation comments to the committee around who should be tested for CKD, identifying CKD and

## Kidney Suite Post-Consultation meeting minutes

recommendations for research.

The committee provided their feedback on how to respond to stakeholder comments and the Chair thanked YM for her presentation.

### **6. AOB, Summary and next steps**

Attendees of the meeting were invited to raise anything further for discussion under any other business.

JL provided the Committee with an overview of the next key deadlines for this topic.

The Chair thanked the Committee for their time and contributions to the meeting and the overall guideline development.

**Date of next meeting:** 30/06/2021

**Location of next meeting:** Virtual